New evidence strengthens case for intravenous iron in acute settings

A large retrospective study published in May 2026 examined more than 85,000 hospitalized patients who had both iron-deficiency anemia and an acute bacterial infection. Researchers found that those who received intravenous iron showed higher survival rates at 14 and 90 days compared with matched patients who did not receive the treatment. Hemoglobin recovery was also greater in the intravenous iron group across multiple infection types, including pneumonia, urinary tract infections, cellulitis, and MRSA bacteremia.

The analysis used propensity matching to compare outcomes. Survival differences reached statistical significance in each subgroup examined. Patients given intravenous iron did not experience longer hospital stays or more transfusion days. The findings appear in the journal Blood and were highlighted by the American Society of Hematology.

Lead author Haris Sohail noted that the data suggest intravenous iron does not worsen infections and may support better overall recovery when iron stores are low during illness.

Heart failure outcomes improve with iron repletion

A 2025 meta-analysis in Nature Medicine pooled individual participant data from six major trials involving more than 7,000 patients with heart failure and iron deficiency. Intravenous iron reduced the composite rate of recurrent heart failure hospitalizations and cardiovascular mortality by 28 percent at 12 months and 19 percent over the full follow-up period. Both components of the endpoint contributed to the benefit, with the largest effects seen in the first year when dosing was highest.

All-cause mortality showed a directionally positive but not statistically significant reduction. The analysis supports earlier trial results and indicates that treating iron deficiency in this population can lower cardiovascular events without increasing safety signals.

Broader advantages across chronic conditions

Systematic reviews and meta-analyses published in 2025 compared intravenous iron with oral iron in several populations. Intravenous formulations produced statistically significant greater increases in hemoglobin among patients with chronic kidney disease, inflammatory bowel disease, cancer-related anemia, and general iron-deficiency anemia. Correction occurred faster, and gastrointestinal side effects occurred less often.

No significant hemoglobin difference appeared in postoperative anemia or restless legs syndrome in the pooled data. Patient-specific factors such as absorption capacity and urgency of correction guide choice between routes.

Earlier work from Johns Hopkins Medicine reviewed tens of thousands of surgical cases and reported lower mortality and morbidity when preoperative anemia was addressed with iron infusions rather than red blood cell transfusions.

Photo by Brett Jordan on Unsplash

How modern intravenous iron works

Intravenous iron delivers elemental iron directly into the bloodstream through a small catheter placed in a vein. Modern preparations such as ferric carboxymaltose, iron sucrose, and ferric derisomaltose allow larger doses in shorter times than older dextran-based products. The iron binds to transferrin and is used for hemoglobin synthesis or stored as ferritin.

Because the route bypasses the gastrointestinal tract, it succeeds when oral absorption is impaired by inflammation, celiac disease, or heavy menstrual bleeding. A single infusion can deliver 1,000 milligrams or more in 15 to 30 minutes at many centers.

Procedure and recovery expectations

Before treatment, clinicians calculate the required dose based on body weight and current hemoglobin. Patients report medical history and allergies. During the infusion, vital signs are monitored. Observation for at least 30 minutes afterward checks for any reaction.

Most people notice symptom improvement within several days to a week. Full repletion of stores and correction of anemia can take up to two months. Follow-up blood tests confirm response.

Common mild effects include headache, nausea, or temporary changes in blood pressure. Serious reactions remain rare with current formulations.

Who benefits most from this approach

Clinicians often recommend intravenous iron for patients who cannot tolerate or absorb oral supplements, those with moderate to severe deficiency requiring rapid correction, and specific groups such as pregnant individuals with significant anemia, people on dialysis, or those preparing for major surgery. It also serves individuals with ongoing blood loss or inflammatory conditions that raise hepcidin and block oral uptake.

Oral iron remains appropriate for milder cases without absorption barriers. Cost and logistics of clinic visits influence decisions in some health systems.

Photo by Pawel Czerwinski on Unsplash

Balancing evidence on safety

Earlier meta-analyses raised questions about possible increased infection risk with intravenous iron. The 2026 real-world study of patients already experiencing acute infections found no evidence of harm and instead documented survival gains. Ongoing monitoring and individualized assessment continue to shape practice.

Some formulations carry a risk of transient hypophosphatemia. Providers screen and manage this when indicated.

Global context and access considerations

Iron deficiency affects hundreds of millions worldwide. Research on intravenous options has expanded access in high-resource settings and informs guidelines in lower-resource regions where oral therapy logistics or tolerability limit success. Updated trial data help clinicians weigh options for diverse patient populations.